MIRM241220C50000
- 0.95
- -0.86-47.51%
Mirum Pharmaceuticals Newsroom
Analysts Are Bullish on These Healthcare Stocks: Annexon Biosciences (ANNX), Mirum Pharmaceuticals (MIRM)
Evercore Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $68
Mirum Pharmaceuticals Price Target Maintained With a $66.00/Share by HC Wainwright & Co.
Morgan Stanley Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $60
A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $50 to $70
Mirum Pharmaceuticals Is Maintained at Outperform by Baird
Mirum Pharmaceuticals Analyst Ratings
Promising Outlook for Mirum Pharmaceuticals: Buy Rating Justified by Strong Performance and Strategic Initiatives
Leerink Partners Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $49
Mirum Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $66
Evercore ISI Raises Price Target on Mirum Pharmaceuticals to $66 From $62, Keeps Outperform Rating
Morgan Stanley Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)
Optimistic Buy Rating for Mirum Pharmaceuticals Amidst Strong Sales Growth and Expanded LIVMARLI Label
Mirum Pharmaceuticals (MIRM) Receives a Buy From Evercore ISI
Mirum Pharmaceuticals Price Target Raised to $66.00/Share From $62.00 by Evercore ISI Group
Mirum Pharmaceuticals Analyst Ratings
Mirum Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $66
Buy Rating Affirmed for Mirum Pharmaceuticals Amidst Label Expansion and Positive EU Authorization